| Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells V Patel, K Balakrishnan, E Bibikova, M Ayres, MJ Keating, WG Wierda, ... Clinical Cancer Research 23 (14), 3734-3743, 2017 | 140 | 2017 |
| Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199) VM Patel, K Balakrishnan, M Douglas, T Tibbitts, EY Xu, JL Kutok, ... Leukemia 31 (9), 1872, 2017 | 79 | 2017 |
| Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy VK Patel, B Lamothe, ML Ayres, J Gay, JP Cheung, K Balakrishnan, ... Leukemia 32 (4), 920, 2018 | 35 | 2018 |
| Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells V Patel, K Balakrishnan, MJ Keating, WG Wierda, V Gandhi Blood 125 (7), 1126-1136, 2015 | 33 | 2015 |
| Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia V Patel, LS Chen, WG Wierda, K Balakrishnan, V Gandhi Leukemia & lymphoma 55 (4), 899-910, 2014 | 30 | 2014 |
| Decrease in total protein level of Bruton’s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes F Cervantes-Gomez, VK Patel, P Bose, MJ Keating, V Gandhi Leukemia 30 (8), 1803, 2016 | 28 | 2016 |
| Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia V Patel, MJ Keating, WG Wierda, V Gandhi Leukemia & lymphoma 57 (6), 1494-1497, 2016 | 16 | 2016 |
| Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma A Sarkar, K Balakrishnan, J Chen, V Patel, SS Neelapu, JS McMurray, ... Oncotarget 7 (3), 3461, 2016 | 7 | 2016 |
| Elevated level of BCL-2 is the primary target for inhibition during duvelisib (IPI-145) therapy: ABT-199 neutralizes the resistance mechanism in chronic lymphocytic leukemia VM Patel, K Balakrishnan, R Guerrieri, W Wierda, S O'Brien, V Gandhi Cancer Research 75 (15 Supplement), 2657-2657, 2015 | 3 | 2015 |
| Investigating apoptosis pathway in chronic lymphocytic leukemia: stromal influence and therapeutic activation VM Patel | 2 | 2013 |
| Impact of bone marrow microenvironment on mRNA expression of genes in the apoptotic pathway in CLL cells VM Patel, LS Chen, WG Wierda, K Balakrishnan, V Gandhi Cancer Research 72 (8 Supplement), 1490-1490, 2012 | 1 | 2012 |
| A mechanistic rationale for testing the combination of duvelisib (IPI-145) and venetoclax (ABT-199) in chronic lymphocytic leukemia V Patel, K Balakrishnan, M Douglas, T Tibbitts, J Kutok, R Guerrieri, ... LEUKEMIA & LYMPHOMA 56, 109-110, 2015 | | 2015 |
